Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
EXEL or REGN: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 08'th Feb 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for t
Exelixis (EXEL) Loses -11.72% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 08'th Feb 2024
Exelixis (EXEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
02:16pm, Wednesday, 07'th Feb 2024
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
10:13pm, Tuesday, 06'th Feb 2024
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
Exelixis (EXEL) Reports Q4 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 06'th Feb 2024
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Exelixis (EXEL) Tops Q4 Earnings Estimates
06:26pm, Tuesday, 06'th Feb 2024
Exelixis (EXEL) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to loss of $0.03 per share a year ago.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Monday, 29'th Jan 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
01:16pm, Sunday, 21'st Jan 2024
Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life.
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
12:26pm, Friday, 19'th Jan 2024
Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
12:31pm, Wednesday, 17'th Jan 2024
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
04:22am, Wednesday, 17'th Jan 2024
Exelixis Inc. is a biotech company focused on oncology, with its main products being Cometriq and Cabometyx, which are used for treating thyroid and kidney cancer. The company faces a legal battle aga
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
11:19am, Thursday, 11'th Jan 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
02:17pm, Monday, 08'th Jan 2024
Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
04:05pm, Tuesday, 02'nd Jan 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
